Observational study of MSI-high Hepatobiliary and pancreatic cancer

Observational study of MSI-high Hepatobiliary and pancreatic cancer - Study of MSI-High

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040591

Enrollment

Registered

2020-06-01

Start date

2020-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent Hepatobiliary-pancreatic cancer with high microsatellite instability (MSI-High)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) MSI-High is diagnosed by MSI test kit, which is a companion diagnostic agent, or MSI-High is diagnosed by Foundation One CDx cancer genome profile. 2) Diagnosed as unresectable / recurrent hepato-biliary-pancreatic region cancer clinically / imaging 3) Cytologically or histologically diagnosed as cancer (including Group IV and class IV) 4) The person's consent has been obtained in writing.

Exclusion criteria

Exclusion criteria: If it is difficult to obtain consent

Design outcomes

Primary

Measure	Time frame
Efficacy of pembrolizumab	—

Countries

Japan

Contacts

Public ContactMaruki Yuta

National Canser Center Department of Hepatobiliary and Pancreatic Oncology

ymaruki@ncc.go.jp03-3542-2511

Outcome results